Search

Your search keyword '"Angelico M"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Angelico M" Remove constraint Author: "Angelico M" Topic female Remove constraint Topic: female
56 results on '"Angelico M"'

Search Results

1. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

2. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

3. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

4. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

5. Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

6. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]

7. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients

8. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

9. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study

10. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients

11. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

12. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

13. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C

14. Patterns of chronic hepatitis B in Central Italy: a cross-sectional study

15. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C

16. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation

17. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

18. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C

19. One-Year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation

21. Qualitative patterns of biliary bile acids affect cyclosporine intestinal absorption in liver transplant recipients

22. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up

23. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients

24. Plasma lipid lipoproteins and biliary lipid composition in female gallstone patients

25. The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO)

27. [Serum bile acids in congestive heart failure]

28. The effects of maintenance doses of FK506 versus cyclosporin a on glucose and lipid metabolism after orthotopic liver transplantation

29. Sequential changes in serum and biliary bile acids after liver transplantation

30. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

31. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

32. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

33. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

34. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

35. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

36. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

37. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

38. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome

39. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

40. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching

41. Outcomes of Liver Transplant for Adults With Wilson’s Disease

42. A hyper-glycosylation of HBV surface antigen correlates with HBsAg-Negativity at immunosuppression-driven HBV reactivation in vivo and hinders HBsAg recognition in vitro

43. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

44. HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets

45. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

46. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

47. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

48. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

49. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

50. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Catalog

Books, media, physical & digital resources